Commonwealth Equity Services LLC Acquires Shares of 1,058,725 Aquestive Therapeutics, Inc. $AQST

Commonwealth Equity Services LLC bought a new position in shares of Aquestive Therapeutics, Inc. (NASDAQ:AQST) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 1,058,725 shares of the company’s stock, valued at approximately $5,918,000.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. AQR Capital Management LLC raised its holdings in shares of Aquestive Therapeutics by 12.2% in the first quarter. AQR Capital Management LLC now owns 129,019 shares of the company’s stock valued at $374,000 after buying an additional 14,025 shares during the last quarter. First National Bank & Trust Co. of Newtown acquired a new stake in Aquestive Therapeutics in the 2nd quarter valued at about $50,000. USAdvisors Wealth Management LLC bought a new position in shares of Aquestive Therapeutics in the second quarter worth about $33,000. Penbrook Management LLC raised its stake in shares of Aquestive Therapeutics by 93.0% in the second quarter. Penbrook Management LLC now owns 43,585 shares of the company’s stock worth $144,000 after acquiring an additional 21,000 shares during the last quarter. Finally, Daymark Wealth Partners LLC acquired a new position in shares of Aquestive Therapeutics during the second quarter worth approximately $58,000. 32.45% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of analysts recently weighed in on AQST shares. Citigroup reissued an “outperform” rating on shares of Aquestive Therapeutics in a report on Thursday, October 9th. Piper Sandler lifted their target price on Aquestive Therapeutics from $5.00 to $8.00 and gave the company an “overweight” rating in a research note on Friday, November 7th. Zacks Research upgraded Aquestive Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Friday, October 17th. Wall Street Zen raised Aquestive Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, November 8th. Finally, JMP Securities lifted their price objective on Aquestive Therapeutics from $9.00 to $12.00 and gave the stock a “market outperform” rating in a research report on Thursday, October 9th. Two investment analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Buy” and a consensus target price of $8.83.

Aquestive Therapeutics Stock Up 2.9%

NASDAQ:AQST opened at $3.52 on Thursday. Aquestive Therapeutics, Inc. has a 12-month low of $2.12 and a 12-month high of $7.55. The stock’s fifty day simple moving average is $5.84 and its 200-day simple moving average is $5.25. The firm has a market capitalization of $429.45 million, a P/E ratio of -4.96 and a beta of 1.66.

Aquestive Therapeutics (NASDAQ:AQST) last released its quarterly earnings data on Wednesday, November 5th. The company reported ($0.14) EPS for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.01). The company had revenue of $12.81 million during the quarter, compared to analyst estimates of $12.94 million. As a group, equities research analysts expect that Aquestive Therapeutics, Inc. will post -0.46 earnings per share for the current year.

Aquestive Therapeutics Profile

Aquestive Therapeutics, Inc is a specialty pharmaceutical company focused on the development and commercialization of novel drug delivery systems. Leveraging its proprietary PharmFilm® technology, Aquestive designs thin-film formulations that facilitate sublingual, buccal and oral delivery of small molecules, offering rapid onset of action and improved patient compliance compared with traditional dosage forms.

The company’s lead product, Libervant® (diazepam) Buccal Film, is approved by the U.S.